BioSpace News Archive

Assertio Holdings, Inc., a specialty pharmaceutical company offering differentiated products to patients, announced the pricing of its offering of $60 million aggregate principal amount of 6.50% convertible senior notes due 2027 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced the appointment of Simon Tarsh, seasoned financial consultant with experience in the life science industry, to its board of directors at BWV’s annual meeting.

March of Dimes is excited to announce its recognition in more than a dozen marketing and communication industry awards in 2022 recognizing outstanding leadership in public relations, as well as work in creative video production, integrated campaign development and more.

Assertio Holdings, Inc., a specialty pharmaceutical company offering differentiated products to patients, announced its intention to offer, subject to market and other conditions, $60 million aggregate principal amount of convertible senior notes due 2027 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Opiant Pharmaceuticals, Inc. (Opiant) (NASDAQ: OPNT) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Opiant’s pipeline candidate OPNT004 (drinabant) for the treatment of cannabinoid hyperemesis syndrome (CHS), a condition among cannabis users that leads to repeated and severe bouts of vomiting.

BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics, today reported financial results for the quarter ended June 30, 2022.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a series of publications concluding that sotagliflozin’s differentiated dual SGLT1 and SGLT2 mechanism of action may have implications for cardiovascular disease.

Amneal Pharmaceuticals, Inc. announced its support of the creation of the bipartisan Congressional Domestic Pharmaceutical Manufacturing Caucus.

Invacare Corporation (NYSE: IVC) today announced that it has entered into a cooperation agreement with its largest shareholder, Azurite Management LLC (“Azurite”), which currently owns approximately 10.3% of the company’s outstanding shares as of June 30, 2022.

Albireo Pharma, Inc., a rare liver disease company developing novel bile acid modulators, announced the grant of inducement restricted stock units to acquire 17,300 shares of Albireo’s common stock.